---
title: Hemostemix Financial Documents
description: Access Hemostemix's comprehensive financial statements, regulatory documents, and investor resources, including quarterly and annual filings.
---

[![LOGO\_Primary](https://investors.hemostemix.com/hubfs/LOGO_Primary.png)](https://hemostemix.com?hsLang=en)

![menu](https://f.hubspotusercontent40.net/hubfs/7479797/menu.png)

![close\_24px](https://7479797.fs1.hubspotusercontent-na1.net/hubfs/7479797/close_24px.svg)

[Latest News](https://hemostemix.com/latest-news?hsLang=en)

[Investors](https://investors.hemostemix.com/?hsLang=en) / Financials

FINANCIALS

 

# Financial statements and MD&A. Easy to find, complete.

Every quarterly and annual filing, available as an individual PDF. Audited annual statements, interim statements and Management's Discussion & Analysis are listed by fiscal year, newest first.

[View Latest Filing](https://investors.hemostemix.com/financials#latest)

[Hemostemix on SEDAR+](https://www.sedarplus.ca/csa-party/records/profile.html?id=ca49a7148a98de1c311c77e0a97c2c96)

TSXV: HEM     OTCQB: HMTXF     FSE: 2VF0 

DOCUMENT LIBRARY

## Financial filings by year

**2026** to date

[Download all 2026 (ZIP)](https://investors.hemostemix.com/hubfs/2026_Hemostemix_AGM_%26_TO_DATE_Financials_%26_MD%26A.zip?hsLang=en)

|  | [2026 Hemostemix AGM Notice of Meeting](https://investors.hemostemix.com/hubfs/Hemostemix%20AGM%20NC%2048p.pdf?hsLang=en) |
| --- | --- |
|  | [2026 AGM Hemostemix BEN](https://investors.hemostemix.com/hubfs/Hemostemix%20AGM%20TVZQ.BEN_ia.E.39204.pdf?hsLang=en) |
|  | [2026 AGM Sedar Proxy English](https://investors.hemostemix.com/hubfs/Hemostemix%20AGM%20TVZQ_SEDAR_Proxy_English.pdf?hsLang=en) |
|  | [2026 AGM Combined FNS and MD&A Proxy Mailing](https://investors.hemostemix.com/hubfs/Hemostemix%20AGM%20_combined%20FNS%20and%20MD%26A_pdf_%20proxy%20mailing.pdf?hsLang=en) |
|  | [Q2 2026 Interim Financial Statements](https://investors.hemostemix.com/hubfs/Financials/Hemostemix_-_Q2_2026_-_FINAL_FS_08-31-2026.pdf?hsLang=en) |
|  | [Q2 2026 Management Discussion & Analysis](https://investors.hemostemix.com/hubfs/Financials/Hemostemix_-_Q2_2026_-_FINAL_MDA_08-31-2026.pdf?hsLang=en) |
|  | [Q1 2026 Interim Financial Statements](https://investors.hemostemix.com/hubfs/Financials/Hemostemix_-_Q1_2026_-_FINAL_FS_05-29-2026.pdf?hsLang=en) |
|  | [Q1 2026 Management Discussion & Analysis](https://investors.hemostemix.com/hubfs/Financials/Hemostemix_-_Q1_2026_-_FINAL_MDA_05-29-2026.pdf?hsLang=en) |

 

**2025**

[Download all 2025 (ZIP)](https://investors.hemostemix.com/hubfs/2025_Hemostemix_Financials_%26_MD%26A.zip?hsLang=en)

|  | [2025 Annual Audited Financial Statements](https://investors.hemostemix.com/hubfs/Financials/Hemostemix_-_Q4_2025_-_FINAL_FS_04-30-2026.pdf?hsLang=en) |
| --- | --- |
|  | [2025 Annual Management Discussion & Analysis](https://investors.hemostemix.com/hubfs/Financials/Hemostemix_-_Q4_2025_-_FINAL_MDA_-_04-30-2026.pdf?hsLang=en) |
|  | [Q3 2025 Interim Financial Statements Restatement](https://investors.hemostemix.com/hubfs/Financials/Hemostemix_-_Q3_2025_-_Financial_statements_-_Restatement_06-18-2026.pdf?hsLang=en) |
|  | [Q3 2025 Management Discussion & Analysis Restatement](https://investors.hemostemix.com/hubfs/Financials/Hemostemix_-_Q3_2025_-_MDA_-_Restatement_06-18-2026.pdf?hsLang=en) |
|  | [Q3 2025 Interim Financial Statements](https://investors.hemostemix.com/hubfs/Financials/Hemostemix_-_Q3_2025_-_FINAL_FS_11-28-2025.pdf?hsLang=en) |
|  | [Q3 2025 Management Discussion & Analysis](https://investors.hemostemix.com/hubfs/Financials/Hemostemix_-_Q3_2025_-_FINAL_MDA_11-28-2025.pdf?hsLang=en) |
|  | [Q2 2025 Interim Financial Statements](https://investors.hemostemix.com/hubfs/Financials/Hemostemix_-_Q2_2025_-_FINAL_FS_08-29-2025.pdf?hsLang=en) |
|  | [Q2 2025 Management Discussion & Analysis](https://investors.hemostemix.com/hubfs/Financials/Hemostemix_-_Q2_2025_-_FINAL_MDA_08-29-2025.pdf?hsLang=en) |
|  | [Q1 2025 Interim Financial Statements](https://investors.hemostemix.com/hubfs/Financials/Hemostemix_-_Q1_2025_-_Final_FS_05-30-2025.pdf?hsLang=en) |
|  | [Q1 2025 Management Discussion & Analysis](https://investors.hemostemix.com/hubfs/Financials/Hemostemix_-_Q1_2025_-_Final_MDA_05-30-2025.pdf?hsLang=en) |

 

**2024**

[Download all 2024 (ZIP)](https://investors.hemostemix.com/hubfs/2024_Hemostemix_Financials_%26_MD%26A.zip?hsLang=en)

|  | [2024 Annual Audited Financial Statements](https://investors.hemostemix.com/hubfs/Financials/Hemostemix_-_Q4_2024_-_FS_FINAL-2.pdf?hsLang=en) |
| --- | --- |
|  | [2024 Annual Management Discussion & Analysis](https://investors.hemostemix.com/hubfs/Financials/Hemostemix_-_Q4_2024_-_FINAL_MDA_04-29-2025.pdf?hsLang=en) |
|  | [Q3 2024 Interim Financial Statements](https://investors.hemostemix.com/hubfs/Financials/Hemostemix_-_Q3_2024_-_FINAL_FS_11-29-2024.pdf?hsLang=en) |
|  | [Q3 2024 Management Discussion & Analysis](https://investors.hemostemix.com/hubfs/Financials/Hemostemix_-_Q3_2024_-_FINAL_MDA_11-29-2024.pdf?hsLang=en) |
|  | [Q2 2024 Interim Financial Statements](https://investors.hemostemix.com/hubfs/Financials/Hemostemix_-_Q2_2024_-_Final_FS_08-29-2024.pdf?hsLang=en) |
|  | [Q2 2024 Management Discussion & Analysis](https://investors.hemostemix.com/hubfs/Financials/Hemostemix_-_Q2_2024_-_Final_MDA_08-29-2024.pdf?hsLang=en) |
|  | [Q1 2024 Interim Financial Statements](https://investors.hemostemix.com/hubfs/Financials/Q1Mar2024_FS_Hemo.pdf?hsLang=en) |
|  | [Q1 2024 Management Discussion & Analysis](https://investors.hemostemix.com/hubfs/Financials/Q1Mar2024_MDA_Hemo.pdf?hsLang=en) |

 

**2023**

[Download all 2023 (ZIP)](https://investors.hemostemix.com/hubfs/2023_Hemostemix_Financials_%26_MD%26A.zip?hsLang=en)

|  | [2023 Annual Audited Financial Statements](https://investors.hemostemix.com/hubfs/Financials/Q42023_FS_Hemo.pdf?hsLang=en) |
| --- | --- |
|  | [2023 Annual Management Discussion & Analysis](https://investors.hemostemix.com/hubfs/Financials/Q42023_MDA_Hemo.pdf?hsLang=en) |
|  | [Q3 2023 Interim Financial Statements](https://investors.hemostemix.com/hubfs/Financials/Q3_2023_FS_Hemo.pdf?hsLang=en) |
|  | [Q3 2023 Management Discussion & Analysis](https://investors.hemostemix.com/hubfs/Financials/Q3_2023_MD%26A_Hemo.pdf?hsLang=en) |
|  | [Q2 2023 Interim Financial Statements](https://investors.hemostemix.com/hubfs/Financials/Q2June2023_FS_Hemostemix.pdf?hsLang=en) |
|  | [Q2 2023 Management Discussion & Analysis](https://investors.hemostemix.com/hubfs/Financials/Q2June2023_MD%26A_Hemostemix.pdf?hsLang=en) |
|  | [Q1 2023 Interim Financial Statements](https://investors.hemostemix.com/hubfs/Financials/Q1Mar2023_FS.pdf?hsLang=en) |
|  | [Q1 2023 Management Discussion & Analysis](https://investors.hemostemix.com/hubfs/Financials/Q1Mar2023_MD%26A.pdf?hsLang=en) |

 

<https://www.sedarplus.ca/csa-party/records/profile.html?id=ca49a7148a98de1c311c77e0a97c2c96>

###### Complete Regulatory Record

All continuous disclosure documents, including press releases, AIFs and certifications, are filed on SEDAR+. 

 

**Investor Resources**

 

- [Investor 2-Pager](https://investors.hemostemix.com/hubfs/2_Pager_Q4_2026.pdf?hsLang=en)
- [Investor Deck](https://investors.hemostemix.com/hubfs/Hemostemix_Investor_Deck_Q4_2026_Final.pdf?hsLang=en)
- [Latest News](https://hemostemix.com/latest-news?hsLang=en)

 

**Family Office Data Room**

**Where interest meets diligence**

 

[**Request Access**](https://hemostemix.com/thomas-smeenk?hsLang=en)

Investor Contact

[Thomas Smeenk, President & CEO](https://investors.hemostemix.com/thomas-smeenk?hsLang=en)

[tsmeenk@hemostemix.com](mailto:tsmeenk@hemostemix.com)

+1-905-580-4170

 

 

IMPORTANT NOTICE

ACP-01 is an investigational therapy and has not been approved by the U.S. Food and Drug Administration or Health Canada. Information provided on this website is for educational purposes only and does not constitute medical advice. Patients should consult a qualified healthcare professional regarding diagnosis and treatment decisions.

 

FORWARD-LOOKING STATEMENTS

This website contains forward-looking statements regarding clinical, regulatory, manufacturing and commercial plans. These reflect current expectations and are subject to risk and uncertainty. Actual results may differ materially. Investors should review all public disclosures on SEDAR+ before making investment decisions.  

 

FLORIDA NOTICE

This notice is provided in accordance with Florida law. One or more physicians referenced may perform stem cell therapies that have not been approved by the United States Food and Drug Administration. Patients are encouraged to consult with their primary care provider before undergoing any stem cell therapy.

[![LOGO\_Primary](https://investors.hemostemix.com/hubfs/LOGO_Primary.png)](https://hemostemix.com/?hsLang=en)

Contact Us